DOP2002000429A - Imidazotriazinas - Google Patents

Imidazotriazinas

Info

Publication number
DOP2002000429A
DOP2002000429A DO2002000429A DO2002000429A DOP2002000429A DO P2002000429 A DOP2002000429 A DO P2002000429A DO 2002000429 A DO2002000429 A DO 2002000429A DO 2002000429 A DO2002000429 A DO 2002000429A DO P2002000429 A DOP2002000429 A DO P2002000429A
Authority
DO
Dominican Republic
Prior art keywords
imidazotriazinas
preparation
imidazotriazines
prophylaxis
medicaments
Prior art date
Application number
DO2002000429A
Other languages
English (en)
Inventor
David Bruckner
Martin Hendrix
Karl-Heinz Schlemmer
Marcus Bauser
Paul Naab
Dietmar Flubacher
Ulrich Niewohner
Jens-Kerim Erguden
Nils Burkhardt
Arno Friedl
Irene Gerlach
Volker Hinz
Reinhard Jork
Thorsten-Oliver Repp
Juergen Stoltefub
Dagmar Schaub
Adrian Tersteegen
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of DOP2002000429A publication Critical patent/DOP2002000429A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a nuevas imidazotriazinas, a procedimientos para su preparación y a su uso para la preparación de medicamentos para el tratamiento y/o la profilaxis de enfermedades neurodegenerativas, especialmente de la enfermedad de parkinson.
DO2002000429A 2001-06-22 2002-06-21 Imidazotriazinas DOP2002000429A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10130167A DE10130167A1 (de) 2001-06-22 2001-06-22 Imidazotriazine

Publications (1)

Publication Number Publication Date
DOP2002000429A true DOP2002000429A (es) 2003-10-15

Family

ID=7689090

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2002000429A DOP2002000429A (es) 2001-06-22 2002-06-21 Imidazotriazinas

Country Status (11)

Country Link
US (1) US6936609B2 (es)
EP (1) EP1404677A1 (es)
JP (1) JP2004534827A (es)
AR (1) AR036103A1 (es)
CA (1) CA2451525A1 (es)
DE (1) DE10130167A1 (es)
DO (1) DOP2002000429A (es)
GT (1) GT200200122A (es)
PE (1) PE20030129A1 (es)
SV (1) SV2003001107A (es)
WO (1) WO2003000693A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7576080B2 (en) * 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
KR101532256B1 (ko) 2006-11-22 2015-06-29 인사이트 코포레이션 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
WO2008119057A2 (en) 2007-03-27 2008-10-02 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
US8637528B2 (en) * 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
DE102007060172A1 (de) 2007-12-13 2009-06-25 Bayer Healthcare Ag Triazolotriazine und Triazolopyrazine und ihre Verwendung
DE102008035209A1 (de) 2008-07-29 2010-02-04 Bayer Schering Pharma Aktiengesellschaft Triazolotriazine und Triazolopyrazine und ihre Verwendung
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
JP5290406B2 (ja) * 2008-09-04 2013-09-18 田辺三菱製薬株式会社 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用
EP2342191B1 (en) * 2008-09-10 2013-03-20 Mitsubishi Tanabe Pharma Corporation Aromatic nitrogen-containing 6-membered ring compounds and their use
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
EP2539342B1 (en) * 2010-02-26 2015-04-15 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compounds and their use as pde10 inhibitors
WO2011141713A1 (en) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
KR20130083389A (ko) * 2010-05-28 2013-07-22 바이오크리스트파마슈티컬즈,인코포레이티드 야누스 키나아제 억제제로서 헤테로사이클릭 화합물
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
KR20160105948A (ko) 2010-11-08 2016-09-07 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
KR20140009372A (ko) 2011-02-18 2014-01-22 알러간, 인코포레이티드 포스포다이에스테라제 10(pde10a)의 억제제로서의 치환된 6,7-다이알콕시-3-아이소퀴놀리놀 유도체
PE20140236A1 (es) 2011-02-23 2014-03-14 Pfizer IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS
JP2014231475A (ja) * 2011-08-25 2014-12-11 田辺三菱製薬株式会社 新規化合物及びそのｐｄｅ１０阻害薬としての使用
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
EP2963037B1 (en) 2013-02-27 2019-03-27 Mochida Pharmaceutical Co., Ltd. Novel pyrazole derivative
CA2910759C (en) 2013-05-02 2018-01-16 Pfizer Inc. Imidazo-triazine derivatives as pde10 inhibitors
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
CN111825675B (zh) * 2019-04-15 2023-08-01 武汉朗来科技发展有限公司 Rock抑制剂及其制备方法和用途
CN119768172A (zh) 2022-08-18 2025-04-04 米托迪治愈有限责任公司 具有磷酸二酯酶-7抑制活性的治疗剂在治疗和预防与慢性疲劳、衰竭和/或劳累不耐受有关的疾病中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
DK109578A (da) 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
NZ504436A (en) * 1997-11-12 2001-08-31 Bayer Ag 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
WO2001024781A2 (en) 1999-10-07 2001-04-12 Novaneuron Inc. Gene necessary for striatal function, uses thereof, and compounds for modulating same

Also Published As

Publication number Publication date
JP2004534827A (ja) 2004-11-18
GT200200122A (es) 2003-06-05
SV2003001107A (es) 2003-03-18
AR036103A1 (es) 2004-08-11
CA2451525A1 (en) 2003-01-03
PE20030129A1 (es) 2003-03-13
EP1404677A1 (de) 2004-04-07
US20040249148A1 (en) 2004-12-09
WO2003000693A1 (de) 2003-01-03
DE10130167A1 (de) 2003-01-02
US6936609B2 (en) 2005-08-30

Similar Documents

Publication Publication Date Title
DOP2002000429A (es) Imidazotriazinas
BR0213358A (pt) Uso de flibanserina
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
MXPA05011208A (es) Uso de ivermectina para el tratamiento de desordenes dermatologicos.
BRPI0410029A (pt) dihidroquinazolinas substituìdas
BR0208636A (pt) Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com inf‰ncia
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
LTC1425001I2 (lt) Fenetanolamino dariniai, skirti kvėpavimo ligoms gydyti
HN1999000124A (es) Derivados de pirazol substituido.
BRPI0407234A (pt) Heterociclos substituìdos
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
BR0213684A (pt) Uso de antagonistas do receptor de endotelina para o tratamento de doenças tumorìgenas
UY28313A1 (es) Nonadepsipeptidos acilados
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
UY27733A1 (es) Derivados de ciclopenteno.
SV2003001061A (es) Nuevos heterociclos 3 ref.lea 35361-sv
DOP2001000140A (es) Aril y heteroarilsulfonatos
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos
UY26945A1 (es) Alcanosulfonatos de fenoxifenilo
UY27348A1 (es) Imidazotriazinas
EA200100876A2 (ru) Фармацевтическая композиция для предупреждения или лечения заболевания, связанного с избыточным продуцированием il-12
WO2003000269A3 (de) Neue verwendung für pde 10a-inhibitoren
DOP2001000253A (es) Alcanosulfonatos de fenoxifenilo.
DOP2002000404A (es) Nuevos heterocuclos 3.